The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index; 83 of the 162 sources its claims cite were checked for support.
Primary biliary cholangitis.
Open accessAbstract
Narrative review of epidemiology, pathogenesis, and current and emerging treatment of PBC.
Overview
CoChat Summary
TL;DR
Primary biliary cholangitis is a chronic autoimmune cholestatic disease with rising incidence worldwide and a decreasing female-to-male ratio, driven by genetic susceptibility, environmental triggers, immune dysregulation, and biliary epithelial injury. Management now includes ursodeoxycholic acid, obeticholic acid, and PPAR agonists, with emerging goals of alkaline phosphatase normalisation and improved symptom-related quality of life.
Key findings
- Pooled global incidence is 1·76 and prevalence 14·6 per 100 000 people per year; the female-to-male ratio has fallen from 9:1 to 4:1 over 20 years. Regional incidence is 2·75 in North America, 1·86 in Europe, and 0·84 in Asia-Pacific per 100 000 people per year, with prevalence 21·81, 14·59, and 9·82, respectively.
- Diagnosis requires at least two of biochemical chronic cholestasis, positive anti-mitochondrial antibodies, and compatible histology; elevated alkaline phosphatase plus positive anti-mitochondrial antibody is sufficient without biopsy. Anti-gp210 and anti-sp100 have low sensitivities (23% and 25%) but high specificity (>95%) in anti-mitochondrial antibody-negative disease.
- Ursodeoxycholic acid is standard of care: 10-year liver transplant-free survival was 79·7% with versus 60·7% without treatment, with a hazard ratio of 0·46 (95% CI 0·40–0·52, p<0·001). In phase 3 trials, elafibranor met the primary endpoint in 50·9% versus 3·8% with placebo, and seladelpar in 61·7% versus 20·0%; alkaline phosphatase normalisation occurred in 15% and 25%, respectively.
- Hepatocellular carcinoma incidence is 3·4–3·6 per 1000 patient-years overall and 15·7 per 1000 patient-years in cirrhosis; osteoporosis risk is increased 3·3-fold. Fatigue affects more than 50% of patients and pruritus 20–80%.
Methods
- Design: narrative Lancet Seminar/review, not primary research; it synthesises epidemiology, pathogenesis, diagnosis, and management of primary biliary cholangitis.
- Data: published literature including meta-analyses, genome-wide association studies, randomised controlled trials (e.g., POISE, ELATIVE, RESPONSE), real-world cohorts, and clinical practice guidelines; no new patient sample or primary data collection.
- Analysis: narrative synthesis with figures and tables summarising pathogenesis, diagnostic approach, and clinical trials of PPAR agonists and symptom-directed therapies.
Limitations
- Stated: current data on the efficacy of combination therapy, particularly long-term prognosis and safety, are insufficient; evidence supporting bisphosphonate use for osteoporosis in primary biliary cholangitis remains insufficient; PPAR agonist phase 3 trials excluded patients with advanced fibrosis, so these agents are unlikely to be indicated in that group; and the benefit of alkaline phosphatase normalisation derives from retrospective ursodeoxycholic acid monotherapy data and requires prospective real-world validation for second-line therapies.
- Evident from the text: as a narrative Seminar, no systematic search strategy, inclusion criteria, or risk-of-bias assessment is described, and many cited management and prognosis data are retrospective or real-world.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
60 Valid · 9 Not valid · 58 Not checked · 35 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“After 24 weeks of treatment, the changes in the primary biliary cholangitis with a -40 fatigue domain score were encouraging: +2•4 for placebo, +0•3 for setanaxib 400 mg daily, and -9•9 for 400 mg twice daily groups (p=0•027).116,117”
§ Primary biliary cholangitis > Symptom management
What the sources say
- Supportedcites [116] Invernizzi, 2023, Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial, Liver Int source
The Introduction summary (p. 1) and Figure 5/Figure 2 legends (Discussion, pp. 4-5) of our copy give exactly these Week 24 values for the PBC-40 fatigue domain: +0.3% (SD 24.9%) for setanaxib 400 mg OD, -9.9% (19.8%) for 400 mg BID, +2.4% (23.1%) for placebo, with p = .027 for the BID-versus-placebo difference (mean difference -12.2; 95% CI -22.9 to -1.4). The citing sentence reproduces all three numbers and the p-value faithfully; the values are percentage changes and the p-value in the source compares the BID group with placebo only, which does not alter the attributed content. (LLM, conf=0.90)
- Disputedcites [117] Jones, 2023, Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial, Hepatol Commun sourceExperimental — accuracy not yet measured
The Abstract’s Results report different week-24 PBC-40 fatigue-score changes for all three groups: +0.6 for placebo, −0.8 for setanaxib 400 mg once daily, and −3.6 for 400 mg twice daily. The paper describes these quality-of-life analyses as descriptive; it does not report the claimed p=0.027 for these changes. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The characteristic histopathological lesion in primary biliary cholangitis, chronic non-suppurative destructive cholangitis, involves lymphocytic infiltration and destruction of the biliary epithelia of small-calibre to medium-calibre interlobular bile ducts (figure 1), 6 ultimately leading to bile duct destruction (ductopenia) and cholestasis.”
§ Primary biliary cholangitis > Introduction
What the sources say
- Partly supportedcites [6] Nakanuma, 1979, Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis, Gastroenterology sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Escherichia coli has been proposed as a molecular mimic to produce antimitochondrial antibodies based on homologies between human pyruvate dehydrogenase complex (PDC)-E2 and E coli PDC-E2.31”
§ Primary biliary cholangitis > Environmental triggers
What the sources say
- Supportedcites [31] Wang, 2014, Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD).B6 (Idd10/Idd18) mice, Clin Exp Immunol source
The Discussion describes previously reported cross-reactivity between human PDC-E2 and its E. coli counterpart as consistent with molecular mimicry. The Results report that E. coli infection elicited antimitochondrial antibodies in mice. Our copy provides section labels but no page numbers. (LLM, conf=0.91)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent genome-wide meta-analysis revealed novel risk loci, including ID2, TMEM163, PRDM1, CCR6, ETS1, and FAM177A1.18”
§ Primary biliary cholangitis > Genetic susceptibility
What the sources say
- Supportedcites [18] Cordell, 2021, An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs, J Hepatol source
Table 2A in the Results section lists all six named genes at newly identified or newly confirmed PBC risk loci with replicated association evidence. The table identifies them as candidate genes at the loci, not necessarily the genes to which the associations map. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, pruritus, fatigue, and symptoms of associated auto immune diseases, such as sicca syndrome (dry eyes and mouth), adversely affect the health-related quality of life (HRQOL) of patients with primary biliary cholangitis”
§ Primary biliary cholangitis > Introduction
What the sources say
- Partly supportedcites [7] Dyson, 2016, The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis, Aliment Pharmacol Ther sourceExperimental — accuracy not yet measured
The Introduction says that pruritus and fatigue can significantly affect quality of life in patients with primary biliary cholangitis; the Results also show higher itch and fatigue scores among patients reporting poor quality of life. Our copy does not identify sicca syndrome or symptoms of associated autoimmune diseases as contributors to that impairment (section labels provided; page numbers unavailable). (LLM, conf=0.88)
- Partly supportedcites [8] Montali, 2021, Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison, J Transl Autoimmun sourceExperimental — accuracy not yet measured
The Introduction says that fatigue is a major determinant of reduced quality of life in PBC and lists pruritus among common symptoms. The Discussion also examines itch and dryness, and the Methods identify dryness as a quality-of-life questionnaire domain. However, our copy does not identify dryness as sicca syndrome (dry eyes and mouth) or attribute it to an associated autoimmune disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
86 more claims · 37 with their cited sources checked
Create a free account to see all 162 claims and to verify the 7 references still open.
- Borderline: one of the tests for a substantial claim is unclear. 2
- It may state two separate claims as one. 53
- Probably not a substantial claim. 28
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Primary biliary cholangitis > More ambitious treatment goals
“all current phase 3 clinical trials have used POISE criteria (alkaline phosphatase <1•67 times ULN, alkaline phosphatase ≥15% decrease, or bilirubin ≤ULN) 87 as the primary endpoint”
§ Primary biliary cholangitis > Obeticholic acid
“the primary composite endpoint, defined as alkaline phosphatase less than 1•67 times the upper limit of normal (ULN) with more than 15% reduction from baseline and bilirubin within the normal range (POISE criteria).87”
Citations
Cites
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 3×
“3,4,55 A large multicentre retrospective study involving 3985 patients showed that LSM assessed by vibration-controlled transient elastography provided a better prognostic ability than biochemical response.”
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · cited 12×
“87 Based on this result, the European Medicines Agency and the US Food and Drug Administration (FDA) authorised conditional marketing approval of obeticholic acid as second-line therapy with final approval contingent on demonstration of improved patient outcomes in the phase 4, placebo-controlled,…”
InfluentialMack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983 · cited 1×
“51 Hypercholesterolaemia and elevated IgM are also clinically useful biochemical markers of primary biliary cholangitis.”
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913 · cited 3×
“4 Although invasive liver biopsy is not routinely required for the diagnosis of anti-mitochondrial antibody-positive primary biliary cholangitis, biopsies should be performed in patients without primary biliary cholangitis-specific autoantibodies or to identify comorbid liver diseases, such as…”
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Gershwin, E. M., Selmi, C., Worman, H. J., Gold, E. B., Watnik, M., Utts, J., Lindor, K. D., Kaplan, M. M., & Vierling, J. M. (2005) · Hepatology · doi:10.1002/hep.20907 · Cited by 621
Self-citationPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Tang, R., Wei, Y., Li, Y., Chen, W., Chen, H., Wang, Q., Yang, F., Miao, Q., Xiao, X., Zhang, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313332 · Cited by 434 · cited 2×
“diversity of the intestinal microbiome is decreased in treatment-naive primary biliary cholangitis patients 34,35 with a unique intestinal microbiota composed of elevated levels of Enterobacteriaceae , Pseudomonas , Veillonella , and Clostridium , along with reduced levels of Oscillospira and…”
Self-citation
Cited by
Natural product-derived compounds in clinical trials and drug approvals
Butler, M. S., Capon, R. J., Blaskovich, M. A. T., & Henderson, I. R. (2025) · Natural Product Reports · doi:10.1039/d5np00031a · Cited by 97
Che, H., Gao, Y., Xu, Y., Xu, H., Eils, R., & Tian, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02329-1 · Cited by 64
Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes
Jamalinia, M., Lonardo, A., & Weiskirchen, R. (2024) · Fibrosis · doi:10.70322/fibrosis.2024.10006 · Cited by 49
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications
Geng, Y., & Schwabe, R. F. (2025) · Hepatology · doi:10.1097/hep.0000000000001386 · Cited by 41
Hoy, S. M. (2024) · Drugs · doi:10.1007/s40265-024-02114-4 · Cited by 23
Metadata
- Authors
- Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M.
- Affiliations
- Teikyo University (JP)
- Shanghai Jiao Tong University (CN)
- Fukushima Medical University (JP)
- Baylor College of Medicine (US)
- Corresponding author
- Tanaka, Atsushi
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 404
- Issue
- 10457
- Pages
- 1053-1066
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4401936541
- Cited by
- 177
- References
- 132
- Citations by year
- 2026: 92 · 2025: 77 · 2024: 8
- FWCI
- 12.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Government of Japan Ministry of Health Labour and Welfare
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, autoimmune cholestatic liver disease, incidence trends, sex differences, gut microbiota, environmental triggers, pathogenesis, cholangiocytes, cytokines and chemokines, obeticholic acid, ursodeoxycholic acid, triple therapy, pruritus, fatigue, health-related quality of life, risk stratification, early diagnosis
- MeSH terms
- Gastrointestinal Microbiome, Aged, Chenodeoxycholic Acid, Cholagogues and Choleretics, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Primary biliary cholangitis. https://app.cochat.ai/papers/10.1016/s0140-6736(24)01303-5
- The paper
- Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024). Primary biliary cholangitis. The Lancet. https://doi.org/10.1016/s0140-6736(24)01303-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.